Salinosporamide A (NPI-0052, marizomib) is a naturally occurring
proteasome inhibitor derived from the marine actinobacterium Salinispora tropica, and represents a promising clinical agent in the treatment of
hematologic malignancies. Recently, these actinobacteria were shown to harbor self-resistance properties to
salinosporamide A by expressing redundant catalytically active mutants of the
20S proteasome β-subunit, reminiscent of PSMB5 mutations identified in
cancer cells with acquired resistance to the founding
proteasome inhibitor bortezomib (BTZ). Here, we assessed the growth inhibitory potential of
salinosporamide A in human
acute lymphocytic leukemia CCRF-CEM cells, and its 10-fold (CEM/BTZ7) and 123-fold (CEM/BTZ200)
bortezomib-resistant sublines harboring PSMB5 mutations. Parental cells displayed sensitivity to
salinosporamide A (IC50 = 5.1 nM), whereas their
bortezomib-resistant sublines were 9- and 17-fold cross-resistant to
salinosporamide A, respectively. Notably, combination experiments of
salinosporamide A and
bortezomib showed synergistic activity in CEM/BTZ200 cells. CEM cells gradually exposed to 20 nM
salinosporamide A (CEM/S20) displayed stable 5-fold acquired resistance to
salinosporamide A and were 3-fold cross-resistant to
bortezomib. Consistent with the acquisition of a PSMB5 point mutation (M45V) in CEM/S20 cells,
salinosporamide A displayed a markedly impaired capacity to inhibit β5-associated catalytic activity. Last, compared with parental CEM cells, CEM/S20 cells exhibited up to 2.5-fold upregulation of constitutive
proteasome subunits, while retaining unaltered immunoproteasome subunit expression. In conclusion,
salinosporamide A displayed potent antileukemic activity against
bortezomib-resistant
leukemia cells. β-Subunit point mutations as a common feature of acquired resistance to
salinosporamide A and
bortezomib in hematologic cells and S. tropica suggest an evolutionarily conserved mechanism of resistance to
proteasome inhibitors.